Stockreport

FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults

Intra-Cellular Therapies Inc.  (ITCI) 
Last intra-cellular therapies inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations
PDF NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for ce [Read more]